Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovent BiologicsIVBXF 71 3-Year Share Buyback Ratio is -4.20 as of Jun. 2026. GuruFocus rates IVBXF with a GF Score™ of 71/100 and a GF Value™ of $13.93 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,186 Biotechnology companies, Innovent Biologics ranks better than 68.72% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Innovent Biologics's current 3-Year Share Buyback Ratio was -4.20%.
The historical rank and industry rank for Innovent Biologics's 3-Year Share Buyback Ratio or its related term are showing as below:
IVBXF'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -8.2 Med: -5 Max: -3.9
Current: -4.2
During the past 10 years, Innovent Biologics's highest 3-Year Share Buyback Ratio was -3.90%. The lowest was -8.20%. And the median was -5.00%.
IVBXF's 3-Year Share Buyback Ratio is ranked better than 68.72% of 1186
companies
in the Biotechnology industry
Industry Median: -11.6
vs IVBXF: -4.20
Innovent Biologics (OTCPK:IVBXF) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Innovent Biologics 3-Year Share Buyback Ratio Related Terms
IVBXF vs VRTX, REGN, MRNA: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Innovent Biologics's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's 3-Year Share Buyback Ratio falls into.
Innovent Biologics 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -4.20 mean?
Innovent Biologics (IVBXF) has a 3-Year Share Buyback Ratio of -4.20 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Innovent Biologics and its competitors. According to the industry distribution chart, Innovent Biologics ranks #371 out of 1186 companies in the Biotechnology industry, placing it in the top 31.3%.
Is Innovent Biologics' 3-Year Share Buyback Ratio too high?
Innovent Biologics' current 3-Year Share Buyback Ratio is -4.20. Based on the distribution chart, Innovent Biologics ranks #371 out of 1186 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Innovent Biologics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #371 out of 1186 companies for 3-Year Share Buyback Ratio. This puts Innovent Biologics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Innovent Biologics and its competitors. Innovent Biologics's current 3-Year Share Buyback Ratio is -4.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (IVBXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.93, compared to a current price of $12.36 — trading 11.3% below its estimated fair value. The current 3-Year Share Buyback Ratio is -4.20. Innovent Biologics' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Innovent Biologics (IVBXF), the current 3-Year Share Buyback Ratio is -4.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (IVBXF) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of $12.36 is trading 11.3% below its estimated GF Value™ of $13.93.
GuruFocus considers Innovent Biologics to be Modestly Undervalued.
Key valuation signals for IVBXF:
3-Year Share Buyback Ratio: -4.20
GF Value™: $13.93 vs. price of $12.36 (11.3% below fair value)
No single metric tells the full story. See the IVBXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
71GF Score
Get the complete analysis for IVBXF
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVBXF has been successfully added to your 
